1. Home
  2. Clinical Topics
  3. Oncology
  4. Breast Cancer
  5. FDA approves first PI3K inhibitor for breast cancer
Breast CancerClinical TopicsOncologyOncology Resource CenterUncategorizedWomen's Health

FDA approves first PI3K inhibitor for breast cancer

Share

On May 24, the FDA approved Piqray (alpelisib) tablets, to be used in combination with fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by an FDA-approved test) following progression on or after an endocrine-based regimen.

Read more at fda.gov.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts